| Title |
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
|
|---|---|
| Published in |
Cancer Management and Research, December 2022
|
| DOI | 10.2147/cmar.s391220 |
| Pubmed ID | |
| Authors |
Yoshimasa Shiraishi, Takayuki Shimose, Yuko Tsuchiya-Kawano, Hidenobu Ishii, Haruko Daga, Kentaro Ito, Koichi Saruwatari, Isamu Okamoto |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 2 | 20% |
| Student > Bachelor | 2 | 20% |
| Student > Ph. D. Student | 1 | 10% |
| Unknown | 5 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 1 | 10% |
| Economics, Econometrics and Finance | 1 | 10% |
| Medicine and Dentistry | 1 | 10% |
| Unknown | 7 | 70% |